You are here: Industry Insights > Appili Therapeutics

News List

Appili announces dosing of first patient in phase 3 Covid-19 trial pharmaceutical-business-review
December 07, 2020
Appili Therapeutics announced that first patient has been dosed in the phase 3 PRESECO (preventing severe Covid disease) clinical trial to assess oral Avigan tablets (favipiravir) to treat Covid-19.
Health Canada clears Appili Therapeutics for new phase 3 trial to assess Avigan to prevent Covid-19 pharmaceutical-business-review
November 27, 2020
Appili Therapeutics, a biopharmaceutical company focused on anti-infective drug development, announced initiation of its Phase 3 Post Exposure Prophylaxis for COVID-19 (PEPCO) study to evaluate Avigan tablets (favipiravir) in the prevention of Covid-19.
Appili Therapeutics to partner with Dr Reddy’s, GRA and FUJIFILM for Avigan tablets expresspharma
November 02, 2020
Appili Therapeutics, a biopharma company focused on anti-infective drug development, announced that it has signed a collaboration, development and supply agreement with Dr Reddy’s Laboratories and Global Response Aid (GRA).
FDA clears Appili Therapeutics to expand its trial of favipiravir for prrevention of Covid-19 pharmaceutical-business-review
August 13, 2020
Appili Therapeutics, a biopharmaceutical company focused on anti-infective drug development, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company clearance to proceed after Appili’s filing of ...
Appili set to evaluate favipiravir as preventive measure against Covid-19 pharmaceutical-business-review
May 28, 2020
Appili Therapeutics has secured regulatory clearance from Health Canada to move ahead with a phase 2 study for studying FUJIFILM Toyama Chemical’s favipiravir as a preventative measure against the outbreak of novel coronavirus (Covid-19).
Appili Therapeutics submits CTA with Health Canada to sponsor trial of favipiravir as preventative m pharmaceutical-business-review
May 14, 2020
Appili Therapeutics said that it will sponsor the first clinical trial evaluating FUJIFILM Toyama Chemical’s (FFTC) drug favipiravir for the prevention of COVID-19, a respiratory infection caused by the novel SARS-CoV-2 coronavirus.